Clinical Edge Journal Scan

Pediatric HCC: Histologic subtypes demonstrate distinct clinical patterns


 

Key clinical point: The pediatric hepatocellular carcinoma (HCC) subtypes fibrolamellar carcinoma (FLC) and conventional HCC (cHCC) can be considered nonequivalent entities because they show different anatomic patterns and outcomes together with their known molecular differences.

Major finding: HCC subtypes were significantly different in presentation and behavior, with increased lymph node involvement in FLC and higher stage in cHCC. Multivariate analysis revealed increased mortality in cHCC compared with that in FLC (adjusted hazard ratio 2.2; P = .004).

Study details: These findings are from a multicenter, retrospective review study including 262 patients <20 years of age with hepatocellular neoplasms, including cHCC (n = 110), FLC (n = 119), and tumors with mixed features of HCC and hepatoblastoma (n = 33).

Disclosures: The study was supported by the University of Utah Population Health Research Foundation and National Center for Advancing Translational Sciences of the US National Institutes of Health. Some authors reported receiving research grants or travel support from various sources.

Source: Short SS et al. Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative study. Cancer. 2022 (May 13). Doi: 10.1002/cncr.34256

Recommended Reading

Subsequent anticancer therapy after ICI treatment prolongs survival in HCC
Federal Practitioner
Does imaging surveillance intensity govern clinical outcomes in HCC?
Federal Practitioner
Laparoscopic anatomic hepatectomy achieves better follow-up outcomes than non-anatomical hepatectomy in HCC
Federal Practitioner
Advanced HCC: Immunotherapy vs chemotherapy improves survival
Federal Practitioner
Advanced HCC: Lenvatinib plus nivolumab yields promising results in real-world
Federal Practitioner
Efficacy and safety of tumor vaccines in HCC: Lessons from two decades of research
Federal Practitioner
HCC incidence after successful DAA therapy for hepatitis C varies with cirrhosis status
Federal Practitioner
TIPS plus sequential systemic therapy shows promise in advanced HCC with tumor thrombus-related SPH
Federal Practitioner
Commentary: Immunotherapy Improves Outcomes in Hepatocellular Cancer, June 2022
Federal Practitioner
Radiation segmentectomy: A promising treatment option for well-selected patients with HCC
Federal Practitioner